81.61
price up icon2.90%   2.30
pre-market  Pre-mercato:  82.02   0.41   +0.50%
loading
Precedente Chiudi:
$79.31
Aprire:
$79.87
Volume 24 ore:
10.55M
Relative Volume:
0.69
Capitalizzazione di mercato:
$204.93B
Reddito:
$63.92B
Utile/perdita netta:
$17.43B
Rapporto P/E:
11.88
EPS:
6.87
Flusso di cassa netto:
$17.04B
1 W Prestazione:
+0.11%
1M Prestazione:
+3.23%
6M Prestazione:
-14.71%
1 anno Prestazione:
-35.07%
Intervallo 1D:
Value
$79.87
$81.77
Intervallo di 1 settimana:
Value
$78.95
$82.66
Portata 52W:
Value
$73.31
$128.73

Merck Co Inc Stock (MRK) Company Profile

Name
Nome
Merck Co Inc
Name
Telefono
908-740-4000
Name
Indirizzo
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Name
Dipendente
75,000
Name
Cinguettio
@Merck
Name
Prossima data di guadagno
2025-02-04
Name
Ultimi documenti SEC
Name
MRK's Discussions on Twitter

Confronta MRK con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
MRK
Merck Co Inc
81.61 204.70B 63.92B 17.43B 17.04B 6.87
Drug Manufacturers - General icon
LLY
Lilly Eli Co
776.44 692.83B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
167.93 373.35B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
187.11 329.24B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
116.83 231.66B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
66.78 298.68B 43.59B 15.04B 10.74B 3.3766

Merck Co Inc Stock (MRK) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-14 Downgrade Citigroup Buy → Neutral
2025-04-22 Iniziato Cantor Fitzgerald Neutral
2025-02-18 Downgrade Deutsche Bank Buy → Hold
2025-02-10 Downgrade TD Cowen Buy → Hold
2025-01-08 Downgrade Truist Buy → Hold
2024-12-20 Downgrade BMO Capital Markets Outperform → Market Perform
2024-12-10 Ripresa BofA Securities Buy
2024-12-04 Aggiornamento HSBC Securities Hold → Buy
2024-11-15 Iniziato Wolfe Research Peer Perform
2024-11-11 Downgrade Daiwa Securities Buy → Neutral
2024-10-17 Iniziato Bernstein Mkt Perform
2024-03-11 Downgrade Societe Generale Hold → Sell
2024-01-04 Aggiornamento TD Cowen Market Perform → Outperform
2023-11-09 Iniziato Deutsche Bank Buy
2023-10-27 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-10-20 Aggiornamento UBS Neutral → Buy
2023-07-14 Iniziato HSBC Securities Hold
2023-04-13 Aggiornamento Citigroup Neutral → Buy
2023-03-28 Downgrade Societe Generale Buy → Hold
2023-03-13 Downgrade Wells Fargo Overweight → Equal Weight
2023-03-06 Iniziato Jefferies Buy
2023-02-22 Aggiornamento Wolfe Research Peer Perform → Outperform
2023-01-04 Aggiornamento BofA Securities Neutral → Buy
2022-11-18 Iniziato Credit Suisse Outperform
2022-10-10 Aggiornamento Guggenheim Neutral → Buy
2022-09-14 Aggiornamento Berenberg Hold → Buy
2022-07-06 Aggiornamento Daiwa Securities Neutral → Buy
2022-06-06 Ripresa SVB Leerink Outperform
2022-04-06 Ripresa Morgan Stanley Equal-Weight
2021-12-17 Iniziato Goldman Buy
2021-12-16 Iniziato Daiwa Securities Neutral
2021-12-13 Downgrade UBS Buy → Neutral
2021-12-09 Iniziato Wells Fargo Overweight
2021-12-07 Downgrade Guggenheim Buy → Neutral
2021-11-29 Downgrade Citigroup Buy → Neutral
2021-11-19 Iniziato BMO Capital Markets Market Perform
2021-11-01 Aggiornamento Argus Hold → Buy
2021-09-07 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-07-27 Ripresa Truist Buy
2021-05-20 Downgrade Argus Buy → Hold
2021-04-07 Ripresa RBC Capital Mkts Sector Perform
2020-11-10 Ripresa Bernstein Outperform
2020-09-29 Iniziato Berenberg Hold
2020-08-03 Aggiornamento Goldman Neutral → Buy
2020-06-12 Downgrade Wolfe Research Outperform → Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-01-07 Iniziato RBC Capital Mkts Sector Perform
2019-10-17 Ripresa BofA/Merrill Neutral
2019-08-16 Iniziato SVB Leerink Outperform
2019-07-03 Iniziato Mizuho Buy
2019-05-28 Iniziato Goldman Neutral
2019-05-13 Aggiornamento Atlantic Equities Neutral → Overweight
2018-10-16 Reiterato Citigroup Buy
2018-10-09 Ripresa Guggenheim Buy
2018-04-23 Aggiornamento Goldman Neutral → Buy
2018-04-17 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2018-04-05 Aggiornamento Barclays Equal Weight → Overweight
2018-03-12 Aggiornamento Leerink Partners Mkt Perform → Outperform
2018-02-14 Reiterato Leerink Partners Mkt Perform
2018-02-07 Reiterato Morgan Stanley Equal-Weight
2018-01-16 Aggiornamento SunTrust Hold → Buy
Mostra tutto

Merck Co Inc Borsa (MRK) Ultime notizie

pulisher
02:25 AM

Companion Animal Medicine Market Key Players AnalysisMerck & - openPR.com

02:25 AM
pulisher
01:25 AM

Merck Announces Fourth-Quarter 2025 Dividend - BioSpace

01:25 AM
pulisher
Jul 21, 2025

Lobbying Update: $4,980,000 of MERCK & CO INC lobbying was just disclosed - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Merck & Co., Inc. (MRK) Breaks Ground on $1B Biologics Hub to Boost KEYTRUDA Production - Insider Monkey

Jul 21, 2025
pulisher
Jul 21, 2025

Is Weakness In Merck & Co., Inc. (NYSE:MRK) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects? - 富途牛牛

Jul 21, 2025
pulisher
Jul 21, 2025

Merck Commits to Veeva Vault CRM – Company Announcement - Financial Times

Jul 21, 2025
pulisher
Jul 20, 2025

Morgan Stanley Lowered the Firm’s PT on Merck & Co (MRK), Kept a Hold Rating - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? - The Motley Fool

Jul 20, 2025
pulisher
Jul 19, 2025

MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Jul 19, 2025
pulisher
Jul 18, 2025

Peter Lynch's Investment Strategy: A Detailed Analysis of MERCK & CO INC (MRK) - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Merck’s (MRK) Dividend History: A Track Record of Consistency - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Jefferies Raises Merck (MRK) Price Target, Maintains Buy Rating - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Merck KGaA gets EU nod for Ezmekly (MRK:NYSE) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Livestock Identification Company Evaluation Report 2025 | Merck, Shearwell, Datamars Drive Innovations with Comprehensive Tagging and Tracking Solutions - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Merck’s SWOT analysis: stock faces keytruda patent cliff, gardasil challenges - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Merck’s SWOT analysis: stock faces keytruda patent cliff, gardasil challenges By Investing.com - Investing.com UK

Jul 18, 2025
pulisher
Jul 16, 2025

Why Merck Is A Better Dividend Stock Than Gilead Sciences (NYSE:MRK) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 15, 2025

Merck & Co., Inc. (MRK) Is Unlikely To Face Antitrust Action For Verona Deal, Says Jim Cramer - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention - Yahoo Finance

Jul 15, 2025
pulisher
Jul 14, 2025

The Zacks Analyst Blog Highlights Microsoft, Alibaba Group, Merck, Monarch Cement and Team - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

Merck & Co advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Merck to Start Phase 3 Trials of MK-8527 for HIV Prevention - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill - Business Wire

Jul 14, 2025
pulisher
Jul 13, 2025

Verona Pharma (VRNA) Opinions on Merck Acquisition News - Quiver Quantitative

Jul 13, 2025
pulisher
Jul 12, 2025

Merck & Co., Inc. (MRK)’s CEO Thinks He’s Got $50 Billion Of New Drugs, Says Jim Cramer - MSN

Jul 12, 2025
pulisher
Jul 12, 2025

UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects - MSN

Jul 12, 2025
pulisher
Jul 12, 2025

Key deals this week: Meta, Boyd Gaming, Merck, Sandstorm Gold, Capgemini and more - Seeking Alpha

Jul 12, 2025
pulisher
Jul 12, 2025

Verona Pharma plc (VRNA): Jim Cramer Approves The Merck Acquisition - Yahoo Finance

Jul 12, 2025
pulisher
Jul 11, 2025

Success Tricking FDA Shouldn't Protect Merck, Justices Told - Law360

Jul 11, 2025
pulisher
Jul 11, 2025

Merck to Acquire Verona Pharma in $10B Bid - USA Herald

Jul 11, 2025
pulisher
Jul 11, 2025

Top Analyst Reports for Microsoft, Alibaba & Merck - TradingView

Jul 11, 2025
pulisher
Jul 11, 2025

FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill - Yahoo Finance

Jul 11, 2025
pulisher
Jul 11, 2025

With Verona deal, Merck wagers on strength of lung drug’s patents - BioPharma Dive

Jul 11, 2025
pulisher
Jul 11, 2025

Merck: Jefferies raises TP after Verona acquisition - MarketScreener

Jul 11, 2025
pulisher
Jul 11, 2025

Jefferies Adjusts Merck & Co.'s Price Target to $141 From $138, Keeps Buy Rating - MarketScreener

Jul 11, 2025
pulisher
Jul 11, 2025

Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock? - Nasdaq

Jul 11, 2025
pulisher
Jul 10, 2025

Merck Animal Health gets FDA nod for Bravecto Quantum (MRK:NYSE) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 10, 2025

Merck Animal Health's Flea-and-Tick Treatment Approved in U.S. - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health - Business Wire

Jul 10, 2025
pulisher
Jul 10, 2025

Merck & Co. Remains In The BD Game After Verona Takeout - insights.citeline.com

Jul 10, 2025
pulisher
Jul 10, 2025

Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration - Insider Monkey

Jul 10, 2025
pulisher
Jul 10, 2025

Merck's doravirine/islatravir under FDA review for HIV (MRK:NYSE) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 10, 2025

U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection - Business Wire

Jul 10, 2025
pulisher
Jul 10, 2025

Merck to acquire UK drugmaker Verona Pharma for $10bn - World Pharmaceutical Frontiers

Jul 10, 2025
pulisher
Jul 10, 2025

Foley Represents Verona Pharma in $10B Acquisition by Merck - Foley & Lardner LLP

Jul 10, 2025
pulisher
Jul 09, 2025

Merck (MRK) Rises Higher Than Market: Key Facts - Yahoo Finance

Jul 09, 2025
pulisher
Jul 09, 2025

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory - insights.citeline.com

Jul 09, 2025
pulisher
Jul 09, 2025

In a $10B deal, Merck buys cardio developer Verona - BioWorld MedTech

Jul 09, 2025
pulisher
Jul 09, 2025

Merck spends $10 billion for Verona, gaining access to its COPD medication - Jacksonville Journal-Courier

Jul 09, 2025
pulisher
Jul 09, 2025

Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue (NYSE:MRK) - Seeking Alpha

Jul 09, 2025
pulisher
Jul 09, 2025

Merck to buy Verona and its lung drug in $10B deal - BioPharma Dive

Jul 09, 2025

Merck Co Inc Azioni (MRK) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general NVO
$66.78
price up icon 2.87%
$305.69
price up icon 3.32%
drug_manufacturers_general NVS
$116.83
price up icon 2.36%
drug_manufacturers_general PFE
$25.14
price up icon 3.63%
$110.17
price up icon 1.75%
Capitalizzazione:     |  Volume (24 ore):